Provider Education, Practice Champions Can Ensure Successful Integration of Biosimilars
Healio, Kashyap Patel, MD
Hundreds of millions of people worldwide rely on biologics to manage debilitating conditions and treat serious illnesses. These innovative therapies are particularly significant for patients with cancer, as they provide an alternative to hours of chemotherapy. As the patents of many biologics expire, opportunities to introduce biosimilar products are increasing. Biosimilars are biological products that have been shown to be highly similar to an already-approved biological product. The pre-approved agents are called reference products.
For the full article, check out Healio.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.